Published in Circ Res on July 24, 2008
Diet-induced renal changes in Zucker rats are ameliorated by the superoxide dismutase mimetic TEMPOL. Obesity (Silver Spring) (2009) 1.00
Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J Clin Invest (2013) 0.95
The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res (2008) 0.95
The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research. Clin Biochem (2012) 0.91
Effects of pyrrolidine dithiocarbamate on high-fat diet-induced metabolic and renal alterations in rats. Life Sci (2009) 0.88
Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol (2013) 0.84
Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis. J Biomed Res (2015) 0.80
Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice. Arterioscler Thromb Vasc Biol (2013) 0.79
Beyond genome-wide association studies: the usefulness of mouse genetics in understanding the complex etiology of atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab (2007) 7.19
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev (2009) 5.11
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol (2004) 3.12
Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes (2006) 2.85
Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology (2013) 2.84
IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res (2010) 2.75
Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology (2008) 2.73
Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab (2006) 2.70
Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature (2009) 2.68
Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res (2011) 2.60
Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res (2003) 2.58
Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest (2006) 2.55
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology (2010) 2.53
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 2.32
Overview of nomenclature of nuclear receptors. Pharmacol Rev (2006) 2.21
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler Thromb Vasc Biol (2008) 2.12
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes (2004) 2.12
Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A (2004) 2.08
Regulation of bile acid synthesis by the nuclear receptor Rev-erbalpha. Gastroenterology (2008) 2.06
Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol (2010) 2.03
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis (2003) 2.02
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Retinoid X receptors: common heterodimerization partners with distinct functions. Trends Endocrinol Metab (2010) 1.93
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol Metab (2012) 1.86
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol (2005) 1.84
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Peroxisome proliferator--activated receptor alpha gene regulates left ventricular growth in response to exercise and hypertension. Circulation (2002) 1.79
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor α in mouse liver reveals extensive sharing of binding sites. Mol Cell Biol (2011) 1.77
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem (2003) 1.76
Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes (2011) 1.73
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest (2008) 1.71
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 1.71
Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler Thromb Vasc Biol (2010) 1.70
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.68
Liver X receptor activation stimulates iron export in human alternative macrophages. Circ Res (2013) 1.66
Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse. Gastroenterology (2003) 1.64
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol (2002) 1.63
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol (2005) 1.63
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Atherogenic lipoprotein particles in atherosclerosis. Circulation (2004) 1.63
Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol (2003) 1.61
Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem (2006) 1.60
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood (2002) 1.60
When the Clock stops ticking, metabolic syndrome explodes. Nat Med (2006) 1.59
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab (2004) 1.58
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes (2005) 1.58
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res (2012) 1.55
A fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A (2005) 1.55
Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem (2004) 1.55
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis (2006) 1.54
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med (2003) 1.53
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun (2004) 1.53
Mitochondrial dysfunction as an arrhythmogenic substrate: a translational proof-of-concept study in patients with metabolic syndrome in whom post-operative atrial fibrillation develops. J Am Coll Cardiol (2013) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol (2004) 1.48